Health+Benefits

What are Congress’ Priorities in 2019?

The 116th Congress officially opened earlier this month with 100 new members being sworn in.
By Katie King Posted on January 25, 2019

The 116th Congress officially opened earlier this month with 100 new members being sworn in. The new House Democratic majority largely believes that it has a mandate to protect pre-existing conditions and lower drug costs in the current health environment and intends to prioritize shoring up the ACA and the individual market before considering Medicare expansion legislation. This is welcome news to our efforts to preserve Employer-Sponsored Insurance (ESI).

The Single-Payer Debate

As a reminder, The Council was a founding member of Partnership for America’s Health Care Future (PAHCF), a coalition whose mission is to support efforts to strengthen employer-provided healthcare coverage and to deliver affordable, accessible and expanded options for care. PAHCF just produced its first video in a campaign aimed at destabilizing support around progressive proposals, like Medicare for All.

Prescription Drugs are a Major Focus

In other news, the government is hindering Congress’ ability to shine light on their health policy efforts, but nevertheless, they are wasting no time. The House Oversight and Reform Committee launched a sweeping investigation into how the industry sets its prices, in one of the broadest drug pricing investigations in decades.

Meanwhile, the new House Energy and Commerce Chair, Frank Pallone, announced that increasing generic drug competition “in an atmosphere where often the brand name companies are trying to make that more difficult” is one of his two top drug-pricing priorities. He intends to hold hearings on patent evergreening and product hopping. Both are mechanisms to extend patent protection and keep generic drugs from gaining market share.

And not to be outdone on drug costs, the Republican Chairman of the Senate Finance Committee, Chuck Grassley, established drug pricing as a top priority and will hold the Committee’s first hearing next Tuesday, January 29. This will set the stage for dueling hearings on the topic next week, with the House Oversight Committee holding a hearing on medication costs the same day. Grassley does not support letting the government negotiate the cost of drugs in Medicare, which is a top request of Democrats. He favors policies that focus on antitrust concerns, like ending “pay-for-delay” patent settlements, or stopping brand companies from using FDA safety programs to thwart competition. Both House Democrats and Grassley support allowing the importation of medications from overseas.

Katie King Vice President, Health Policy & Strategy, The Council Read More

More in Health+Benefits

My GLP-1 Journey
Health+Benefits My GLP-1 Journey
While the insurance industry considers whether to cover the drugs for weight los...
Health+Benefits Untangling Prior Authorization
Q&A with Dr. Jack Resneck Jr., Chair of the Department of Dermatology, Universit...
The State of Benefits Satisfaction
Health+Benefits The State of Benefits Satisfaction
Survey results from employee benefits brokers and employers on healthcare costs,...
Five Vision Care Trends to Watch
Health+Benefits Five Vision Care Trends to Watch
Brokers can advise clients on the new possibilities for eye care and how vision ...
Sponsored By EyeMed
No Rest for the Weary
Health+Benefits No Rest for the Weary
The Trump administration has partially stayed federal mental...
The Financial Risk Hiding in Plain Sight
Health+Benefits The Financial Risk Hiding in Plain Sight
Brokers can elevate their client advisory role by addressing...